Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319139 | 1.00 | GHSR (0.44) | GHSRMMP1ALDH1A1MAPTMMP2 | |
| SCHEMBL15533171 | 0.83 | GHSR (0.40) | GHSRALDH1A1MAPTF2 | |
| SCHEMBL867707 | 0.83 | GHSR (0.40) | GHSRALDH1A1MAPTF2 | |
| SCHEMBL867706 | 0.83 | GHSR (0.40) | GHSRALDH1A1MAPTF2 | |
| SCHEMBL10039187 | 0.83 | GHSR (0.40) | GHSRALDH1A1MAPT | |
| SCHEMBL6320100 | 0.82 | GHSR (0.46) | GHSRPIN1 | |
| SCHEMBL6320104 | 0.82 | GHSR (0.46) | GHSRPIN1 | |
| SCHEMBL6319068 | 0.81 | GHSR (0.49) | GHSR | |
| SCHEMBL6319064 | 0.81 | GHSR (0.49) | GHSR | |
| SCHEMBL867525 | 0.81 | GHSR (0.37) | GHSRMMP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | claimed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | claimed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | claimed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | claimed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | GHSR 2/4885MMP1 2132/4885ALDH1A1 2804/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | GHSR 2/4885MMP1 2382/4885ALDH1A1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.